Table 3 Performance characteristics of anti-GP2 and ASCA IgA/IgG and PAB investigating 169 CD patients and 102 UC patients

anti-GP2 IgA

13.0

8.3–19.0

98.0

93.0–99.8

6.6

1.6–27.4

0.9

0.8–1.0

anti-GP2 IgG

28.4

21.7–35.8

92.2

85.1–96.6

3.6

1.8–7.3

0.8

0.7–0.9

anti-GP2 IgA or IgG

30.2

23.4–37.7

91.2

83.9–95.9

3.4

1.8–6.6

0.8

0.7–0.9

ASCA IgA

23.1

17.0–30.2

97.1

91.6–99.4

7.8

2.5–24.7

0.8

0.7–0.9

ASCA IgG

28.4

21.7–35.8

95.1

88.9–98.4

5.8

2.4–14.1

0.8

0.7–0.8

ASCA IgA or IgG

35.5

28.3–43.2

93.1

86.4–97.2

5.2

2.5–10.9

0.7

0.6–0.8

PAB ≥1/20

45.4

37.6–53.4

76.5

67.0–84.3

1.9

1.3–2.8

0.7

0.6–0.8

PAB ≥1/40

38.5

31.1–46.2

79.4

70.3–86.8

1.9

1.2–2.9

0.8

0.7–0.9

at least 1 ab*

50.9

43.1–58.6

85.3

76.9–91.5

3.5

2.1–5.6

0.6

0.5–0.7

at least 2 ab*

27.2

20.7–34.6

97.1

91.6–99.4

9.2

3.0–29.0

0.8

0.7–0.8

at least 3 ab*

10.6

6.4–16.3

100.0

96.4–100.0

∞

0.9

0.8–0.9

at least 4 ab*

4.1

1.7–8.3

100.0

96.4–100.0

∞

1.0

0.1–1.0